Fixed Drug Combinations for the Acute Treatment of Migraine
Author:
- 1 January 2005
- journal article
- Published by Springer Nature in CNS Drugs
- Vol. 19 (9) , 769-784
Abstract
Fixed drug combinations (FDCs) combine standardised doses of two or more drugs in a single tablet, injection, nasal spray or suppository. FDCs may improve treatment compliance, efficacy or tolerability through a variety of mechanisms. At present, FDCs are commonly used in migraine treatment, and more are in development. This systematic review identified 43 prospective trials of FDCs in use for the acute treatment of migraine. Quantitative combination and analysis of the data were not possible, but results of the review support the following qualitative conclusions. First, many FDCs in use for the acute treatment of migraine are older drugs. In these cases, clinical trial evidence that the FDC is efficacious or has important advantages over its treatment components is lacking. The benefits assumed for some common FDC ingredients such as caffeine and metoclopramide are not clearly confirmed in these trials. Secondly, the use of barbiturate-containing FDCs for the acute treatment of migraine is not evidence based, and these drugs are frequently implicated in the development of dependence or medication-induced headache syndromes. Thirdly, studied opioid-containing FDCs are generally superior to placebo, but evidence regarding the safety and tolerability of their repeated use in the treatment of migraine is lacking; clinical experience dictates caution in the use of these agents. Fourthly, ergotamine-containing FDCs are generally superior to placebo, but perform poorly in comparison with single-agent selective serotonin 5-HT1B/1D receptor agonists (‘triptans’), NSAIDs or even isometheptene or opioid comparators, and are less well tolerated. Fifthly, the most consistent and impressive evidence of benefit is for NSAID-containing FDCs. These invariably outperform placebo and are equivalent or superior to active comparators. Finally, with renewed interest in the use of FDCs for the acute treatment of migraine, high-quality evidence of a benefit for such treatments is emerging. An FDC containing a triptan and NSAID seems most likely to provide efficacy and tolerability benefits in the acute treatment of migraine. Such an FDC is in development but not yet approved for use.Keywords
This publication has 43 references indexed in Scilit:
- Acute treatment of migraine. Breaking the paradigm of monotherapyBMC Neurology, 2004
- Comparison of Butorphanol Nasal Spray and Fiorinal With Codeine in the Treatment of MigraineHeadache: The Journal of Head and Face Pain, 1998
- Double-Blind Comparison of An Acetaminophen 400 mg-Codeine 25 mg Combination Versus Aspirin 1000 mg and Placebo in Acute Migraine AttackCephalalgia, 1994
- Polypharmacy in a Headache Centre PopulationHeadache: The Journal of Head and Face Pain, 1993
- Treatment of Migraine Attacks with SumatriptanNew England Journal of Medicine, 1991
- Monotherapy or Polytherapy in MigraineNeuroepidemiology, 1987
- A Treatment for the Acute Migraine AttackJournal of International Medical Research, 1987
- A Combination Drug Treatment for Acute Common MigraineHeadache: The Journal of Head and Face Pain, 1986
- Mild Analgesics as an Alternative to Ergotamine in Migraine. A Comparative Trial with Acetylsalicylic Acid, Ergotamine Tartrate, and a Dextropropoxyphene CompoundThe Journal of Clinical Pharmacology, 1980
- A Comparative Trial of Ergotamine Tartrate, Acetyl Salicylic Acid and a Dextropropoxyphene Compound in Acute Migraine AttacksHeadache: The Journal of Head and Face Pain, 1978